<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2012-0-1-74-76</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-69</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОПЫТ ЛЕЧЕБНЫХ УЧРЕЖДЕНИЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIENCE OF HEALTHCARE FACILITIES</subject></subj-group></article-categories><title-group><article-title>РЕГИОНАРНАЯ ХИМИОИНФУЗИЯ ARTERIA THORACICA INTERNA В КОМБИНИРОВАННОМ ЛЕЧЕНИИ  РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ</article-title><trans-title-group xml:lang="en"><trans-title>REGIONAL CHEMOINFUSION  ARTERIA THORACICA INTERNA IN THE COMBINEITED TREATMENT OF THE BREAST CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Умарова</surname><given-names>К. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Umarova</surname><given-names>K. R.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"><p>Shymkent</p></bio><email xlink:type="simple">karlygash.umarova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арыбжанов</surname><given-names>Д. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Arybzhanov</surname><given-names>D. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шымкент</p></bio><bio xml:lang="en"><p>Shymkent</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орманов</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ormanov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шымкент</p></bio><bio xml:lang="en"><p>Shymkent</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Южно-Казахстанская государственная фармацевтическая академия; Областной онкологический диспансер</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>South Kazakhstan State Pharmaceutical Academy; Regional Cancer Center</institution><country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>26</day><month>01</month><year>2017</year></pub-date><volume>0</volume><issue>1</issue><fpage>74</fpage><lpage>76</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Умарова К.Р., Арыбжанов Д.Т., Орманов А.Н., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Умарова К.Р., Арыбжанов Д.Т., Орманов А.Н.</copyright-holder><copyright-holder xml:lang="en">Umarova K.R., Arybzhanov D.T., Ormanov A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/69">https://www.surgonco.ru/jour/article/view/69</self-uri><abstract><p>Проанализированы  результаты лечения   больных   раком   молочной  железы   III стадии,  получивших  неоадъювантную внутриартериальную химиотерапию по схеме Таксотер 75 мг/м2, Доксорубицин 50 мг/м2. В результате лечения после 2-х курсов химиотерапии частичная  регрессия процесса отмечена у 19 (63,3%) больных, стабилизация  – у 11 (36,7%) больных. После 4-х курсов лечения  полная регрессия отмечена у 15 (50%) больных, частичная регрессия – у 12 (40%) больных, стабилизация процесса – у 3 (10%)  больных. В результате вышеуказанного вида лечения  у 27 (90%) больных удалось произвести радикальную мастэктомию.</p></abstract><trans-abstract xml:lang="en"><p>Direct results  nonadjuvant intraarterial chemotherapy are analysed at breast cancer  3 stages at  30 patients under  scheme  Taxotere  75mg/m2, Doxorubicini  60mg/m2. At the analysis  of  results  after 2 rates  intraarterial chemotherapy partial  regress  at  19 (63,3%) patients, stabilization of process at 11 (36,7%) patients is noted. After 4х rates intraarterial chemotherapy significant regress  of a tumor  is noted at 15 (50%) patients, partial regress at 12 (40%) patients and  stabilization of process  at 3 (10%)  patients. Thus after 4 rates nonadjuvant intraarterial chemotherapy 27 (90%) patients it is lead radical mastectomy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>регионарная химиотерапия</kwd><kwd>рак молочной железы</kwd><kwd>мастэктомия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>regional chemotherapy</kwd><kwd>breast cancer</kwd><kwd>mastectomy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Арзыкулов Ж.А. Сейтказина Г.Д. Показатели онкологической службы Республики Казахстан за 2006г. (статистические материалы). – Алматы, 2005, 66 с.</mixed-citation><mixed-citation xml:lang="en">Арзыкулов Ж.А. Сейтказина Г.Д. Показатели онкологической службы Республики Казахстан за 2006г. (статистические материалы). – Алматы, 2005, 66 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ганцев Ш.Х., Рахматуллина И.Р., Ишмуратова Р.Ш. и др. Новые хирургические технологии для уточнения закономерностей лимфогенного метастазирования при раке // Уральский медицинский журнал. – 2010. – №6. – С. 95–98.</mixed-citation><mixed-citation xml:lang="en">Ганцев Ш.Х., Рахматуллина И.Р., Ишмуратова Р.Ш. и др. Новые хирургические технологии для уточнения закономерностей лимфогенного метастазирования при раке // Уральский медицинский журнал. – 2010. – №6. – С. 95–98.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Гранов А.М., Давыдов М.И., Таразов П.Г., Гранов Д.А. и др. Интервенционная радиология в онкологии (пути развития и технологии). – СПб.: Фолиант, 2007. – С. 88-97.</mixed-citation><mixed-citation xml:lang="en">Гранов А.М., Давыдов М.И., Таразов П.Г., Гранов Д.А. и др. Интервенционная радиология в онкологии (пути развития и технологии). – СПб.: Фолиант, 2007. – С. 88-97.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bonadonna G., Moliterni A., Zambetti M. et al. 30 years’ follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study // BMJ. – 2005. – Vol. 330. – P. 217.</mixed-citation><mixed-citation xml:lang="en">Bonadonna G., Moliterni A., Zambetti M. et al. 30 years’ follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study // BMJ. – 2005. – Vol. 330. – P. 217.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Doughty J.C., Mccarter D.H.A., Kane E. et al. Anatomical basis of intra-arterial chemotherapy for patients with locally advanced breast cancer // Brit. J. Surg. – 1996. – Vol. 83. № 8. – P. 1128-1130.</mixed-citation><mixed-citation xml:lang="en">Doughty J.C., Mccarter D.H.A., Kane E. et al. Anatomical basis of intra-arterial chemotherapy for patients with locally advanced breast cancer // Brit. J. Surg. – 1996. – Vol. 83. № 8. – P. 1128-1130.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kitagava K., Yamakado K., Nakatsuka A. et al. Preoperative transcatheter arterial infusion chemotherapy for locally advanced breast cancer (stage IIIb) for down-staging and increase of respectability // Eur. J. Radiol. – 2002. – Vol. 43. №1. – P. 31-36.</mixed-citation><mixed-citation xml:lang="en">Kitagava K., Yamakado K., Nakatsuka A. et al. Preoperative transcatheter arterial infusion chemotherapy for locally advanced breast cancer (stage IIIb) for down-staging and increase of respectability // Eur. J. Radiol. – 2002. – Vol. 43. №1. – P. 31-36.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Martin M., Pienkoswki T., Mackey J. et al. Adjuvant docetaxel for node positive breast cancer // N. Engl. J. Med. – 2005. – Vol. 352. – P. 2302-2313.</mixed-citation><mixed-citation xml:lang="en">Martin M., Pienkoswki T., Mackey J. et al. Adjuvant docetaxel for node positive breast cancer // N. Engl. J. Med. – 2005. – Vol. 352. – P. 2302-2313.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
